We’re pleased to invite you to an exclusive Executive Briefing with Sen-Jam Pharmaceuticals, taking place next Tuesday, June 3. Whether you saw their recent investor forum presentation or are just beginning to explore their work, this 45-minute session is designed to give you a focused, factual, and forward-looking update on their momentum and milestones.
This session is designed for those tracking their progress and evaluating where they’re headed next. They’ll walk through key updates on their lead programs, including:
- Clinical trial update for SJP-001
- Data readout and insights from SJP-002C’s Phase 2 trial
- Momentum from NIDA on methamphetamine use disorder
- A look at current licensing and partnership activity
They’ll keep it focused, factual, and forward-looking—because they know your time and attention are valuable.
Sen-Jam Pharmaceutical is revolutionizing inflammation management with a patented platform of combination therapeutics designed to act preemptively. With a focus on high-impact markets—respiratory illness, alcohol hangover, and opioid withdrawal—Sen-Jam delivers scalable, de-risked assets poised for rapid commercialization. Their mission: to shift pharma from sick care to proactive health preservation.